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The paper confirms that DBS in young children is safe and can be offered.
Abstract:
Deep brain stimulation (DBS) has been increasingly used for primary and secondary movement disorders in children and young people. Reports of hardware related complications have been sparse for this population and from small cohorts of patients.
We report DBS complications from a single large DBS centre with 10 year experience.
Data was collected as a prospective audit and additionally from a questionnaire on recharging of the stimulators. 129 patients with a minimum 6 months follow up were identified, mean age10.8 y (range 3.0 -18.75), mean follow up 3.3y (range 0.5 -10.3), weight 10.4-94.2kg, 126 new implants (92 Activa RC) and 69 revisions for reasons other than infection. 26 patients were 7y or younger. Surgical site infections (SSI) rates were 10.3% for new implants and revisions, lower 8.6% for new Activa RC and even lower, 4.7%, for new Activa RC in patients under 7y (1/21). SSI occurred within first 6 months and necessitated total system removal in 86% of those infected. Electrode/extension problems were recorded in 18.4% of patients, fracture in 4.6% malfunction in 7.7%, short extension3.8% and electrode migration in 2.3%. Other complications involved clinically silent intracranial bleed in 1 patient, skin erosions (2.3%), unexpected switching off in 18.7% of Soletra/Kinetra and 3.4% of Activa RC, transient seroma at IPG site in postoperative period (8%). Of the 48 returned recharging questionnaires, 38% of families required recharger replacement and 23% experienced frequent problems maintaining connection during recharging. However, 83% of responders considered recharging not at all or only a little care burden.
We identified lower than previously reported DBS infection rates particularly for patients under 7 years, but relatively high incidence of technical problems with electrodes, extensions and in particular recharging. This has to be considered when offering DBS for children with movement disorders.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

Introduction:
Dystonia in childhood is most frequently of a secondary aetiology, is unlikely to remit spontaneously 1 2 and negatively affects a child's life including activity and participation Deep Brain Stimulation has been increasingly used in the management of childhood dystonias. Favourable responses to DBS in primary dystonias have been well documented 7 8 9 10 11 12 and there is growing evidence supporting its use in secondary dystonias, however with more modest effects 13 14 15 .
Complications of DBS in paediatric populations have been sparsely reported in small cohorts of patients. We aim to report complications and discuss challenges of DBS for children from a single large paediatric centre with 10 year experience.
Methods:
Surgery:
All DBS surgeries were performed under general anaesthesia as a one-stage procedure. In the first three years single channel Soletra and double channel Kinetra stimulators were implanted (Medtronic). Once a rechargeable Activa RC stimulator (Medtronic) became available in December 2008 it has been offered preferentially. A Leksell frame was used in all cases, with finger tightening of screws in the very young M A N U S C R I P T
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patients. DBS electrodes were implanted bilaterally through frontal incisions and burr holes into posteromedial globus pallidus interna (GPI) in the majority of patients. Two patients with hemidystonia had unilateral implants (first -unilateral GPI and thalamus, second -unilateral GPI). Three patients had electrodes implanted in subthalamic nucleus (STN) bilaterally due to severe damage of globus pallidus, we reported previously early outcome of STN DBS in the first of these patients 16 . There were two patients with two pairs of electrodes in GPIs, one with additional pair implanted at revision and another with four electrodes implanted at initial procedure. All new DBS patients underwent direct anatomical targeting using pre-operative high-resolution proton density and T1 weighted volume stereotactic brain MRI scans. Medtronic Cases with a minimum of 6 months follow up were entered for further analysis.
Additionally a questionnaire on recharging technique, frequency, duration and any related difficulties was applied to the patients with rechargeable stimulators on the with a minimum 6 months follow up.
Patients'/caregivers' responses were recorded during clinic appointments or over the telephone or filled questionnaires were returned via email.
Simple percentage analysis was used. Within new implants 32 received Soletra and Kinetra stimulators, 92 Activa RC and 2 patients had Activa PC. 22 patients had Soletra and Kinetra stimulators replaced with Activa RC over the course of the study period. When the rechargeable stimulator became available, although we strongly encouraged this type of implant, few patients had a non-rechargeable stimulators implanted due to their/family preference.
29 patients were transitioned to the adult services, 1 patient was lost to follow up. 10
patients died due to underlying natural history of the diagnosis at time points unrelated to surgery (Table 1) . The exception was a patient (case 4 Table 1 ) with AicardiGoutieres Syndrome type 6 who died within 24 hours post DBS electrode revision after an initial normal post-operative recovery -post mortem examination failed to identify cause of death and specifically there was no evidence of an intracranial bleed.
Surgical site infections:
Surgical site infection rate was 8.6% for new Activa RC implants. Overall surgical site infection rate was 10.3% for all new implants and 10.1% for revisions. A lower rate (7.6%) was recorded for patients under 7y at the time of implant (2/26) and even lower rate of 4.7% in a group of patients under 7y with new Activa RC implants (1/21).
All surgical site infections occurred within the first 6 months after surgery. Treatment with prolonged courses of antibiotics was unsuccessful in 86% of patients with surgical site infections following new implants and revisions, necessitating eventually total removal of the DBS system.
Other hardware related complications:
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A clinically insignificant small intracranial bleed was detected on postoperative CT at the site of one electrode in one patient (0.8%) and a self -resolving small CSF collection on the scalp in one patient. Overall, 8% of patients developed self -resolving seromas in the postoperative period, primarily at the battery site.
Three patients (2.3%) developed skin erosions eventually leading to full system explantation in all. One patient developed an unusual granuloma 4 years after the DBS implant and another developed late infection following trauma and haematoma at the stimulator site two years after the surgery.
18.4% of patients experienced problems with electrode leads and extensions:
short/tight extension was observed in 3.8%, electrode migration in 2.3%, electrode/extension fracture in 4.6% and electrode/extension malfunction in 7.7%.
Electrode/extension malfunction was defined as high impedance on at least one contact in monopolar settings (>4000 Ω for Kinetra and Activa; > 2000 Ω for Soletra) or significant fluctuations of therapy current (minimum 50% fluctuations on different measurements of the same therapy settings) including very low current drain.
Two patients (1.5%) remain with the DBS switched off due to perceived intolerable side effects of stimulation, low mood (abullia) relative to previous smiling, likely partially dyskinetic, and ebullience in one and increased rigidity in another.
The IPG was unexpectedly (not related to battery depletion) switched off in 18.7% of patients with Soletra and Kinetra and in 3.4% of patients with Activa RC.
Status dystonicus following disruption of DBS was observed in 6 patients (4.6%) after IPG was switched off unexpectedly in 2 cases, electrode fracture in 1 and system removal in 3.
Complications related to recharging:
Shielded battery syndrome 17 preventing recharging of the neurostimulator due to anterior position of adaptor or rotational flipping over of Activa RC occurred in two cases following replacement of Kinetra with an Activa RC stimulator. With the adaptation of surgical technique no more such cases were observed. Two overweight patients (1.7%)
required Activa RC repositioning due to difficulty recharging.
Questionnaire on recharging:
We obtained 48 completed recharging questionnaires (Fig 2) . Parents and carers were responsible for recharging of the stimulators in 69 % and patients themselves in 29%.
The stimulators were recharged every day or every 2-3 days in the majority of cases (79%) during quiet activities (69%) and the recharging session was shorter than 1 hour in 73%.
Various methods were used to maintain connection between the battery and recharger with the recharger held by hand in most (48%) and original belt or harness used only in 14%.
77% of families have never or only sometimes experienced difficulty maintaining connection, however 14% had difficulty most or all the time.
The recharger had to be replaced due to malfunction in 38% of cases, and twice in 6%.
The battery was reported to be fully discharged (battery flat) at least once in 23%
including 13% more than once.
83% of responders considered recharging of DBS stimulator as 'not at all' or 'only a little' of a care burden.
Discussion:
M A N U S C R I P T This is in contrast to our finding of only 7.6% in our patients under 7 y and even lower 
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Another seven patients developed cellulitis with significantly elevated inflammatory markers.
None of these had permanent sequelae due to DBS infection.
Three patients presented with skin erosion (two over the IPG positioned in the upper chest, one on the scalp) at 11, 42 and 22 months after surgery respectively without signs of infection and negative or inconclusive microbiology results. All of these cases were severely malnourished with body-weights below the 0.4 th centile which we believe contributed to this complication. Our practice has changed since and the stimulators are implanted in the abdomen particularly in patients with low weight.
Electrode leads and extension problems
Complications related to electrodes and extensions were not uncommon in our cohort (18.4%). This is higher that reported in the literature 20 .
In our series, particularly frequent were electrode/extension fractures and malfunction (12.3%). In one case an electrode fracture presented as deterioration of dystonia without typical very high impedances.
Nevertheless, we recommend that the therapy and electrode impedances should be measured during every programming session and particularly when deterioration of symptom control is noted. An X-ray should be performed in cases of high impedance or significant fluctuations of impedance and current or unexplained deterioration of dystonia to exclude an electrode or extension fracture.
Recharging
Rechargeable Activa RC stimulators have been almost exclusively implanted in our centre since December 2008 (Fig 1) due to its small size, important for our population of M A N U S C R I P T
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patients, and to reduce the frequency of battery replacement 32 . Increased risk of implant infection related to higher number of surgical revisions, including IPG replacement, has been reported 33 34 .
Economic savings can be expected from implantation of rechargeable vs nonrechargeable IPG 35 alongside with a high patient satisfaction from rechargeable stimulators 36 37 .
Indeed, the majority of patients/carers in our cohort (84%) indicated that recharging was 'not at all' or 'only a little' care burden. However, a third of families required a recharger replacement and a fifth had frequent difficulty maintaining connection between the recharger and the battery. As previously reported 37 the majority of carers did not use the harness or belt supplied by the manufacturer as they were not suitable either due to patient small size or severe dystonic/dyskinetic movements.
Unexpected IPG switching off, not related to battery failure, occurred in 18.7% of children with Soletra and Kinetra neurostimulators falling to 3.4% in patients with Activa RC implants. This is despite of the fact that a patient control device was offered routinely to all patients with rechargeable stimulators, thus increasing possibility of neurostimulator accidental switching off by patient/carers while patient control device was not supplied for patients with Soletra and Kinetra.
Interestingly 23% of rechargeable stimulators were reported by questionnaire responders (11/48) to be fully discharged at least once. This warrants closer inspection of device usage history at each review point and active reminding about the necessity of and escalation of medication for dystonia was still necessary in some.
Status dystonicus after disruption of DBS
Sudden discontinuation of DBS may result in return of dystonia 39 40 41 . This may occur as a consequence of the system switching off unexpectedly, battery failure, electrode/extension fracture or malfunction. Symptoms can return gradually or lead to severe deterioration including status dystonicus in short order. In our cohort 4.6 % of patients developed difficult-to-treat or refractory status dystonicus after disruption of stimulation and many had milder, more gradual deterioration. Re-institution of DBS where possible led to resolution of symptoms or significantly helped in the management.
Our observation is that severe status dystonicus with active DBS is very rare in patients other than suffering from PKAN and even in these cases treatment is much more difficult when DBS is discontinued. However, we have not formally analysed our cohort to ascertain the incidence of status dystonicus or severe exacerbation of dystonia when receiving active stimulation.
Limitations
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We reported hardware related complications from a large paediatric cohort, however this cohort is not as large as in some adult studies.
DBS for children with dystonia was a relatively new experience at the beginning of data collection, with limited reports on complications available and emergence of new complications with time. This might have resulted in delayed recognition of some problems e.g. electrode malfunction when impedances were high on two vs more contacts. Our patients inevitably move on to the adult services, which are more local to them as opposed to our service accepting referrals often from a great distance. It has an impact on the length of follow up e.g. a patient receiving DBS at 16 years of age will likely leave our service after 2 years.
Conclusions:
DBS in children may be unduly delayed because of concerns of a greater complication risks in young children. We show here that device infection remains the most significant adverse event although with much lower rates than in previously reported small sample case-series of children under 10 years. In particular we do not show increased susceptibility in young patients below 7 years of age. This implies that medical and surgical experience is important in teams delivering DBS to children. This information also supports a practice of safe early DBS in an attempt to mitigate or forestall inevitable co-morbidities such as functional musculoskeletal deformities 42 
